Aquinox Pharmaceuticals Inc., of New York, said it met its enrollment threshold of 300 women in its LEADERSHIP 301 trial of rosiptor (AQX-1125), its SHIP1 activator, in interstitial cystitis/bladder pain syndrome and remains on track for top-line data in the third quarter of 2018.